Use of Rituximab Treatment in Addition to Standard Care for Newly Presenting Thrombotic Thrombocytopenic Purpura
Status:
Withdrawn
Trial end date:
2009-04-01
Target enrollment:
Participant gender:
Summary
The purpose is to evaluate safety and feasibility of the use of Rituximab as an adjunct to
standard therapy (plasmapheresis + steroids) for patients with thrombotic thrombocytopenic
purpura (TTP). This includes evaluating the rate and type of treatment failure.